Natalia Villate, MD
Retina Specialist · Plantation, FLNPI 1902010861
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,873 of the $9,358 with a category attached, or 73.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2024 at $2,341 and has fallen 63.9% since, to $844 in 2025.
Across 180 payments — averaging $51.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Genentech USA, Inc.$2K
- US Oncology Corporate, Inc.$1K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$952
- Eyepoint US, Inc.$315
- plus $2K from 17 others
Across 37 payments — averaging $41.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$2K
What the payments were for
- Travel & lodging$4585%
- Food & beverage$6,87373%
- Education$1021%
- Ownership interest$1,92621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $1,926 |
| Genentech USA, Inc. | 46 | $1,848 |
| US Oncology Corporate, Inc. | 4 | $1,250 |
| AbbVie(2 entities) | 35 | $1,237 |
| Regeneron Healthcare Solutions, Inc. | 29 | $952 |
| Eyepoint US, Inc. | 5 | $315 |
| Genentech, Inc. | 3 | $261 |
| Harrow Eye, LLC | 5 | $220 |
| Amgen | 12 | $216 |
| Astellas Pharma US Inc | 7 | $184 |
| Sandoz | 4 | $152 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Optos, Inc. | 1 | $99 |
| Coherus Oncology, Inc. | 3 | $98 |
| ANI Pharmaceuticals, Inc. | 4 | $93 |
| Novartis | 5 | $89 |
| Mallinckrodt Hospital Products Inc. | 3 | $80 |
| Optovue, Inc. | 1 | $66 |
| Apellis Pharmaceuticals, Inc. | 2 | $52 |
| Rxsight Inc | 2 | $48 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Alcon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,358 in reported general payments places this provider in the 70th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 19 | $50,723 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $6,840 |
| Difluprednate | 27 | $2,713 |
| Prednisolone Acetate | 61 | $2,572 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $764 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $569 |
| Latanoprost | 38 | $463 |
| ValacyclovirValacyclovir Hcl | 14 | $425 |
| Dorzolamide Hcl | 11 | $260 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 29 | $235 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $131 |
| Brimonidine Tartrate | 20 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $952 | $50,72319 claims |
| AbbVieCombigan | $1,237 | $6,84013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Plantation
- Stuart BurgessPlantation$18K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
- Adiel SmithAventura$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.